1. Show article details.

    BRIEF-Fennec Pharmaceuticals Announces Amendment To Increase Existing Senior Debt Facility

    Reuters – 6:03 AM ET 06/26/2020

    Fennec Pharmaceuticals Inc (FENC): * FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY. * Fennec Pharmaceuticals Inc (FENC) - AMENDMENT TO ITS EXISTING SENIOR DEBT FACILITY WITH LIFE SCIENCES GROUP. * Fennec Pharmaceuticals Inc (FENC) - INCREASING SIZE OF FACILITY FROM $12.5 MILLION TO $18 MILLION Source text for Eikon: Further company coverage:

  2. Show article details.

    Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

    GlobeNewswire – 6:00 AM ET 06/26/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on the development of PEDMARK™  for the prevention of platinum-induced ototoxicity in pediatric patients, today announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from $12.5 million to $18 million.

  3. Show article details.

    Fennec Announces Results of Annual Meeting

    GlobeNewswire – 6:03 PM ET 06/22/2020

    Fennec Pharmaceuticals Inc. (FENC) today announced that the nominees listed in the management proxy circular dated May 7, 2020 for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in Costa Mesa, California and online on June 22, 2020.

  4. Show article details.

    BRIEF-Fennec Pharmaceuticals Announces Q1 2020 Financial Results

    Reuters – 6:10 AM ET 05/14/2020

    Fennec Pharmaceuticals Inc (FENC): * FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.19. * Q1 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES DATA. * FDA SET A PDUFA TARGET ACTION DATE FOR PEDMARK OF AUGUST 10, 2020. * COMMERCIAL READINESS ACTIVITIES ARE UNDERWAY IN U.S. Source text for Eikon: Further company coverage:

  5. Show article details.

    Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

    GlobeNewswire – 6:00 AM ET 05/14/2020

    ~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Marketing Authorization Application Validated by the EMA in February 2020 ~~ Strengthened its Financial Position Through a Raise of Approximately $32 Million in Net Proceeds ~~ Commercial Readiness Activities are Underway in the U.S. ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2020 -- Fennec Pharmaceuticals Inc. (FENC), a specialty p...

  6. Show article details.

    Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

    GlobeNewswire – 6:00 AM ET 05/08/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering on May 4, 2020 of $30,000,000 at a price of $6.25 per share, the option granted to the underwriters was exerci...

  7. Show article details.

    Fennec Announces Closing of Public Offering

    GlobeNewswire – 6:00 AM ET 05/05/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share.

  8. Show article details.

    Fennec Announces Pricing of Public Offering

    GlobeNewswire – 9:16 AM ET 04/30/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the pricing of its underwritten public offering of 4,800,000 common shares at a public offering price of $6.25 per share.

  9. Show article details.

    BRIEF-Fennec Reports Proposed Public Offering Of Common Shares

    Reuters – 4:06 PM ET 04/29/2020

    Fennec Pharmaceuticals Inc (FENC): * FENNEC ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES. * Fennec Pharmaceuticals Inc (FENC) - INTENDS TO OFFER ITS COMMON SHARES IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

  10. Show article details.

    Fennec Announces Proposed Public Offering of Common Shares

    GlobeNewswire – 4:01 PM ET 04/29/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on the development of PEDMARK™  for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that it intends to offer its common shares in an underwritten public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the proposed offering.

  11. Show article details.

    BRIEF-Fennec Pharmaceuticals Announces FDA Filing Acceptance For Pedmark

    Reuters – 7:19 AM ET 04/13/2020

    Fennec Pharmaceuticals Inc (FENC): * FENNEC PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR PEDMARK™. * Fennec Pharmaceuticals Inc (FENC) - FDA GRANTS PRIORITY REVIEW AND SETS A PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE OF AUGUST 10, 2020 Source text for Eikon: Further company coverage:

  12. Show article details.

    Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™

    GlobeNewswire – 7:08 AM ET 04/13/2020

    ~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act Target Action Date of August 10, 2020 ~ Research Triangle Park, N.C., April 13, 2020 -- Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration...

  13. Show article details.

    Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™

    GlobeNewswire – 7:00 AM ET 03/05/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 entitled “Method for Reducing Ototoxicity in Pediatric Patients Receiving Platinum-...

  14. Show article details.

    Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

    GlobeNewswire – 6:00 AM ET 02/28/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application for its investigational drug, sodium thiosulfate for infusion,  has passed validation and is now under evaluation by the European Medicines Agency.

  15. Show article details.

    Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

    GlobeNewswire – 6:00 AM ET 02/14/2020

    NDA and Marketing Authorization Application completed in February 2020Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in the second half of 2020Solid financial position with $13.7 million and no debt and the option to access $12.5 million in debt financing upon NDA approval of PEDMARK RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2020 -- Fennec Pharmace...

  16. Show article details.

    Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency

    GlobeNewswire – 6:00 AM ET 02/11/2020

    Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for PEDMARK™  for intravenous use and submitted a Marketing Authorization Application to the European Medicines Agency for sodium thiosulfate.

Page:

Today's and Upcoming Events

  • Aug
    07

    FENC to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    14

    FENC announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.